Canton Strategic Holdings Inc
Canton Strategic Holdings Inc
Your view on CNTN
Overview
What the company does, where it operates, and who runs it.
About Canton Strategic Holdings Inc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Wendland
- Headquarters
- 34 Shrewsbury Avenue, Red Bank, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Wendland
- Headquarters
- 34 Shrewsbury Avenue, Red Bank, NJ, US
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas.
The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development.
Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial.
Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Canton Strategic Holdings Inc, and the rating behind it. CNTN last traded at $2.26; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Canton Strategic Holdings Inc. Starting points for Canton Strategic Holdings Inc: EPS -$0.45, beta 1.48 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Canton Strategic Holdings Inc. Canton Strategic Holdings Inc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Canton Strategic Holdings Inc. Trailing twelve-month EPS for Canton Strategic Holdings Inc stands at -$0.45. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Canton Strategic Holdings Inc. Canton Strategic Holdings Inc has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Canton Strategic Holdings Inc valued side by side against its closest peers. Canton Strategic Holdings Inc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Canton Strategic Holdings Inc, and how their positions are changing. At a $174.3M market value, institutional positions materially move Canton Strategic Holdings Inc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Canton Strategic Holdings Inc executives and directors. Shares of Canton Strategic Holdings Inc have traded between $1.08 and $9.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Canton Strategic Holdings Inc. Canton Strategic Holdings Inc is a $174.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Canton Strategic Holdings Inc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Canton Strategic Holdings Inc. Coverage tracks Canton Strategic Holdings Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.